• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Timing of CSF Biomarker Divergence for Alzheimer Disease, Normal Cognition Varies

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 22, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 21, 2024 -- Cerebrospinal fluid (CSF) and other biomarkers differ for individuals with Alzheimer disease and cognitively normal controls, with the estimated times of divergence varying from 18 to six years before diagnosis, according to a study published in the Feb. 22 issue of the New England Journal of Medicine.

Jianping Jia, M.D., Ph.D., from Xuanwu Hospital in Beijing, and colleagues conducted a multicenter, nested case-control study of Alzheimer disease biomarkers in cognitively normal individuals. At two- to three-year intervals, a subgroup of these participants underwent CSF testing, cognitive assessments, and brain imaging. A total of 648 participants in whom Alzheimer disease developed were matched with 648 participants with normal cognition.

Participants were followed for a median of 19.9 years. The researchers found that CSF and imaging biomarkers in the Alzheimer disease group diverged from those in the cognitively normal group a number of years before diagnosis: amyloid-beta (Aβ)₄₂ at 18 years; ratio of Aβ₄₂ to Aβ₄₀ at 14 years; phosphorylated tau 181 at 11 years; total tau at 10 years; neurofilament light chain at nine years; hippocampal volume at eight years; and cognitive decline at six years. The changes in CSF biomarker levels in the Alzheimer disease group initially accelerated and then slowed as cognitive impairment progressed.

"The importance of the work by Jia et al. cannot be overstated," Richard Mayeux, M.D., from Columbia University in New York City, writes in an accompanying editorial. "Knowledge of the timing of these physiological events is critical to provide clinicians with useful starting points for prevention and therapeutic strategies."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.